Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 267

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 267
---
•the number of, and development requirements for, other product candidates that we pursue; 

•the costs, timing and outcome of regulatory review of our product candidates; 

•our ability to enter into contract manufacturing arrangements for supply of API, and manufacture of our product candidates and the terms of such arrangements;

•our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements; 

•the payment or receipt of milestones and receipt of other collaboration-based revenues, if any; 

•the costs and timing of any future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval; 

•the amount and timing of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; 

•the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; 

•the extent to which we acquire or in-license other products, product candidates, technologies or data referencing rights; 

135

•the enrollment and completion of our Phase 3 clinical trial for Cylembio®, Phase 2 basket trials, and any clinical trials for our existing or future product candidates; 

•the ability to receive additional non-dilutive funding, including grants from organizations, public institutions and foundations; 

•addition of operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts and our transition to a public company; and 

•the costs of operating as a public company. 

Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs. 

Contractual Obligations and Commitments 

In March 2021, we entered into a lease for our office space in Copenhagen, Denmark that was amended in September 2022 and is set to expire in December 2027.  The lease for our office space in Copenhagen, Denmark is terminable upon six months’ notice. In January 2023, we entered into a lease for laboratory space in Copenhagen, Denmark that expires in December 2027. In December  2024, we entered into a